Frontlight ResearchEarly access
CompletedNo phase
Effects of Metyrapone in Patients With Hypercortisolism
Key facts
- Who runs it
- Istituto Auxologico Italiano
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 28 Apr 2022
- Ended
- 31 Dec 2025
- Type of study
- Observational
- Treatments tested
- Metyrapone Capsules
- Record updated
- 30 March 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patients with mild Cushing's Syndrome not candidate for surgery
- Current therapy with metyrapone since less than 1 week
- Cortisol levels at 08:00 after 1 mg-overnight dexamethasone suppression test (1mgDST) >1.8 μg/dL
- Confirmed with 2 mg two days dexamethasone suppression test (2mgx2dDST)
- Presence of at least one out of the following conditions: type 2 diabetes mellitus, impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), arterial hypertension, bone mineral density (BMD) Z-score < -2.0 and/or fragility fracture at any skeletal site
- Stable anti-hypertensive therapies and blood pressure (BP) levels in the month before enrolment
- Stable anti-diabetic therapies and glycometabolic control during the month before enrolment
- Stable body weight during the month before enrolment
Who cannot take part
- Intake of drugs influencing cortisol metabolism and/or secretion
- Malignant hypertension and/or BP <200/120 mmHg
- Possible adrenal metastases or radiological features suggestive for adrenal malignancy (i.e. not homogeneous pattern, necrosis, calcifications, irregular margins, local invasion and high density at computed tomography)
- Severe hyperglycemia (i.e. FG >350 mg/dL)
- Women in child-bearing age
- Signs and/or symptoms of overt hypercortisolism (striae rubrae, moon facies, easy bruising, buffalo hump, hypertrichosis)
- Urinary free cortisol (UFC) higher than 1.5 fold the upper normal range
- Presence of pheochromocytoma or primary hyperaldosteronism
- Congenital adrenal hyperplasia
- Patients with body mass index (BMI) >35 kg/m2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers, mental health and cortisol circadian rhythm.
The group in the trial
- metyrapone treatment
hypercortisolemic patients taking metyrapone since less than a week (usually 250 mg/day, maximum dose 6000 mg/day)
Treatment: Metyrapone Capsules
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism
- Record updated
- 30 March 2026